<DOC>
	<DOCNO>NCT02525861</DOCNO>
	<brief_summary>The purpose study two-fold : ( 1 ) evaluate safety potential immunogenicity GLASSIA follow IV administration via in-line filtration ; , ( 2 ) ass effect GLASSIA augmentation therapy level A1PI various biomarkers epithelial line fluid ( ELF ) follow intravenous ( IV ) administration dosage 60 mg/kg Body weight ( BW ) /week active A1PI protein 25 week subject emphysema due congenital A1PI deficiency .</brief_summary>
	<brief_title>Ph 3/4 GLASSIA Safety , Immunogenicity , Bronchoalveolar Lavage Study</brief_title>
	<detailed_description />
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<criteria>1 . Male female : 1 . For participant undergo bronchoscopy/BAL procedure : 18 65 year age . 2 . For participant waive undergoing bronchoscopy/BAL procedure ( adequate number BAL evaluable participant reach ) : 18 year age old . 2 . A1PI genotype Pi*Z/Z , Pi*Z/Null , Pi*Malton/Z , Pi*Null/Null , `` atrisk '' allelic combination ( exclude MS , MZ , SZ ) 3 . Endogenous plasma ( antigenic ) A1PI level &lt; 8 μM . 4 . Participant must least one follow : clinical diagnosis emphysema , evidence emphysema computerize tomography ( CT ) scan chest , and/or evidence airway obstruction completely reverse bronchodilator treatment time screen . 5 . Participant treat respiratory medication include inhaled bronchodilator , inhaled anticholinergic , inhaled corticosteroid , lowdose systemic corticosteroid ( prednisone ≤10 mg/day equivalent ) , dose participant 's medication remain unchanged least 14 day prior screen . 6 . Participant nonsmoker cease smoke minimum 13 week prior screen ( serum cotinine level screen within normal range nonsmoker ) agree refrain smoke throughout course study . 7 . If female childbearing potential , participant present negative pregnancy test screen agrees employ adequate birth control measure duration study . 8 . Participant willing able comply requirement protocol . 9 . Participant must pulmonary function time screen meeting follow : 1 . Postbronchodilator force expiratory volume 1 second ( FEV1 ) ≥50 % predict 2 . If FEV1 &gt; 80 % predict , FEV1/forced vital capacity ( FVC ) must &lt; 0.7 . **Note : Inclusion criterion # 8 applicable participant enrol target 15 18 evaluable participant reach therefore required undergo bronchoscopy/BAL procedure . 1 . Participant experience history clinically significant pulmonary disease ( COPD , emphysema , chronic bronchitis , mild bronchiectasis , stable asthma ) . 2 . Participant experience history cor pulmonale . 3 . Participant routinely produce one tablespoon sputum per day . 4 . Participant history frequent pulmonary exacerbation ( great 2 moderate severe exacerbation within 52 week prior screen . 5 . Participant experience pulmonary exacerbation time screen ( participant may rescreened 4 week clinical resolution exacerbation ) . 6 . Participant clinically significant abnormality ( emphysema , chronic bronchitis , mild bronchiectasis ) detect chest Xray CT scan time screen . ( Past record obtain within 52 week prior screen may use , available . ) 7 . Participant clinically significant abnormality detect 12lead electrocardiogram ( ECG ) perform time screening . ( Past record obtain within 26 week prior screen may use , available . ) 8 . Participant clinically significant congestive heart failure New York Heart Association ( NYHA ) Class III/IV symptom . 9 . Participant experience active malignancy history malignancy within 5 year prior screen , exception following : adequately treat basal cell squamous cell carcinoma skin , carcinoma situ cervix , stable prostate cancer require treatment . 10 . Participant history lung organ transplant , currently transplant list , undergone major lung surgery . 11 . Participant receive longterm aroundtheclock oxygen supplementation . ( The following allow : shortterm use oxygen supplementation ( eg , management acute COPD exacerbation ) , oxygen supplementation require night time , supplemental oxygen continuous positive airway pressure ( CPAP ) bilevel positive airway pressure ( BiPAP ) ) . 12 . Known history hypersensitivity follow infusion human blood blood component . 13 . Immunoglobulin A ( IgA ) deficiency ( &lt; 8 mg/dL screening ) . 14 . Abnormal clinical laboratory result obtain time screen meeting follow criterion : 1 . Serum alanine aminotransferase ( ALT ) &gt; 3.0 time upper limit normal ( ULN ) 2 . Serum total bilirubin &gt; 2.0 time ULN 3 . &gt; 2+ proteinuria urine dipstick analysis 4 . Serum creatinine &gt; 2.0 time ULN 5 . Absolute neutrophil count ( ANC ) &lt; 1500 cells/mm^3 6 . Hemoglobin ( Hgb ) &lt; 9.0 g/dL 7 . Platelet count &lt; 100,000/mm^3 15 . Ongoing active infection hepatitis A virus ( HAV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) Type 1/2 infection time screen . 16 . Participant clinically significant medical , psychiatric , cognitive illness , uncontrolled medical condition ( eg , unstable angina , transient ischemic attack ) , opinion investigator , would impede participant 's ability comply study procedure , pose increase risk participant 's safety , confound interpretation study result . 17 . Participant participate another clinical study involve investigational product investigational device within 30 day prior enrollment schedule participate another clinical study involve investigational product device course study . 18 . Participant family member employee investigator . 19 . If female , participant nursing time screen . 20 . Participant contraindication ( ) bronchoscopy recent myocardial infarction , unstable angina , cardiopulmonary instability , tracheal obstruction stenosis , moderate severe hypoxemia degree hypercapnia , unstable asthma , Stage 4 5 chronic kidney disease , pulmonary hypertension , severe hemorrhagic diathesis , cervical C1/C2 arthritis . 21 . Participant lung surgery may interfere bronchoscopy . 22 . Known history allergic/hypersensitivity reaction medication use perioperative care associate bronchoscopy/BAL procedure , local anesthetic , sedative , pain control medication . 23 . Participant receive require longterm ( &gt; 4 week ) immunosuppressive therapy , systemic corticosteroid dos great 10 mg/day prednisone ( equivalent ) , mycophenolate mofetil , azathioprine , cyclophosphamide , rituximab . 24 . If participant receive anticoagulant antiplatelet therapy ( warfarin clopidogrel ) , participant unwilling unable safely discontinue anticoagulant antiplatelet therapy within 7 day prior least 24 hour BAL procedure . An exception lowdose aspirin alone allow . Note : Exclusion criterion # 20 , 21 , 22 , 23 , 24 applicable participant enrol target 15 18 evaluable participant reach therefore required undergo bronchoscopy/BAL procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>